Key Takeaways J&J gained FDA approval for Inlexzoh to treat BCG-unresponsive bladder cancer.Inlexzoh approval highlights J&J's advancing pipeline and product launches.J&J oncology sales rose 21.1% in H1 2025, led by older and newer cancer drugs.Johnson & Johnson (JNJ) announced that the FDA has granted approval to a key treatment, TAR-200 (gemcitabine intravesical system), for high-risk non-muscle invasive bladder cancer (NMIBC). This first-of-its-kind drug-releasing system, to be marketed by the name of In ...